|Articles|May 1, 2019
- Pharmaceutical Executive-05-01-2019
- Volume 39
- Issue 5
Pharmaceutical Executive, May 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive May 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 7 years ago
Impact Investing and R&Dalmost 7 years ago
New Flare-Up in Europe's External Reference Pricing Debatealmost 7 years ago
It’s Time for a Chief Adherence Officeralmost 7 years ago
Adopting New Technology: Barriers and Breakthroughsalmost 7 years ago
The CFO Evolutionalmost 7 years ago
We’ve Got You Coveredalmost 7 years ago
Survey Spotlights the CFO’s Strategic Risealmost 7 years ago
FDA After Gottlieb: Thorny Issues, Political Challengesalmost 7 years ago
Easing the Path to Profitabilityalmost 7 years ago
A Strategic Approach to Pharma R&D Portfolio PlanningNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Market
2
The Turning Point for Oral Biologics: Q&A With Morten Graugaard
3
FDA’s Shift Signals a New Era for Data-Driven Drug Development
4
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
5